Furthermore, treatment with IL-2 in low doses was able to reestablish the Treg cell niche, in addition to clinically improving patients’ clinics with vasculitis induced by the hepatitis C virus (HCV) without any significant adverse effects [68]. Here, IL2 is linked to vasculitis.